Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...
Hosted on MSN1mon
Ultragenyx’s Evkeeza secures EU approval for young children with rare cholesterol disorderEvkeeza was discovered and developed by Regeneron Pharmaceuticals, which markets the therapy in the US, whereas Ultragenyx is responsible for its development and commercialisation outside the US.
Who are the leading players in the Evkeeza market? Key players in the Evkeeza market include the notable Regeneron Pharmaceuticals Inc., contributing significantly to the market growth.
Please note that Evkeeza was originally discovered and developed by Regeneron Pharmaceuticals REGN. In 2022, Ultragenyx signed a licensing agreement with Regeneron for Evkeeza to treat HoFH.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results